An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke

Inclusion Criteria: * 1\. Age: 18-80 years old； * 2\. Patients with anterior circulation cerebral infarction; * 3\. first stroke onset or past stroke without obvious neurological deficit (mRS score≤1)； * 4\. Within 24 hours of onset； * 5\. 5 ≤NIHSS score ≤ 20； * 6\. Signed informed consent. Exclusion Criteria: * 1\. Patients with hereditary abnormal glucose and lipid metabolism (gangliosidosis, such as Tay-Sachs disease and retinal degeneration); * 2\. Hemorrhagic stroke; * 3\. Disturbance of consciousness (NIHSS1a≥1)，or cerebral arteritis, brain tumor, brain trauma, intracranial infectious diseases; * 4\. Planed endovascular treatment; * 5\. Uncontrolled hypertension: systolic pressure ≥200 mmHg or diastolic pressure ≥110 mmHg; * 6\. Bleeding tendency (except for thrombolysis) or severe bleeding within 3 months; * 7\. Patients with malignant tumor or serious diseases; * 8\. Along with epilepsy, arthritis and other disease, which have effect on neurological assessment; * 9\. History of autoimmune diseases, spinal trauma, various demyelinating diseases, including acute inflammatory demyelinating polyneuropathy (Guillain Barre syndrome); * 10\. Unable or unwilling to cooperate due to mental diseases; * 11\. Abnormal liver and renal function: ALT, AST \> 2 times of the upper limit of normal value, or Cr \> 1.5 times of the upper limit of normal value； * 12\. Hypersensitivity to monosialoganglioside and excipients of test drug; * 13\. History of drug abuse； * 14\. Pregnant or lactating women, pregnant plan or unwilling to use effective contraception during the trial period; * 15\. Participating in other clinical trials within 3 months; * 16\. Other conditions which are unsuitable for this trial assessed by researcher.